Skip to the main content.
TALK TO AN EXPERT Submit Your RFP
TALK TO AN EXPERT Submit Your RFP
Facebook Instagram Linkedin X YouTube Medium
Other Therapy Areas

Extending our scientific depth across allergy, dermatology, ophthalmology, respiratory, women's health, and more.

Learn More →

John Balser

Veristat and AOBiome Establish a Preferred Partnership To Support Ongoing & Impending Clinical Programs

SOUTHBOROUGH, MA –  June 19, 2017 – Veristat, a full service Clinical Research Organization (CRO), announced today that Veristat and AOBiome, a clinical-stage life sciences company advancing patented microbiome-targeted therapies for systemic and local inflammatory conditions, have entered into a Preferred Provider Agreement (PPA). 

Veristat Acknowledged on Boston Business Journal’s “Fast 50” List for a Second Consecutive Year

Ranked as one of the Top 50 Fastest Growing Private Companies in Massachusetts

Veristat Appoints James Roach, MD as Chief Medical Officer

Veristat Strengthens its Clinical Operations, Medical and Regulatory Affairs Offerings

...

Veristat Formalizes its Strategic Decision Consulting Services

SOUTHBOROUGH, MA –  November 01, 2016 – Veristat, a full-service consultative Clinical Research...

Veristat Strengthens Its Long-Standing Relationship with Aegerion Pharmaceuticals

Veristat, a full service Clinical Research Organization (CRO), announced today the signing of a...

Veristat to Assist on Adaptive Enrichment Design Trial for Verastem’s Defactinib in Mesothelioma

Input Will Drive Trial Design for Lead Cancer Stem Cell-Targeting Program

September...

Veristat’s Collaboration with Aegerion Contributes to FDA Approval of Juxtapid™

Veristat’s Strategic Guidance Contributes to Successful Approval of Aegerion’s Novel Drug Juxtapid

Variance Development Partners Makes a Growth Investment in Veristat

Investment Will Enable Veristat to Further Enhance its Market Leadership Position and...